Insulet | PODD - Sales Revenues

Stock Price
242.80
Daily Change
-8.44 -3.36%
Monthly
-17.51%
Yearly
-15.60%
Q1 Forecast
247.93

Insulet reported $706.3M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
Abbott USD 11.46B 90M Dec/2025
Align Technology USD 1.05B 54.3M Dec/2025
AtriCure USD 134.3M 1.8M Sep/2025
Avanos Medical USD 177.8M 2.8M Sep/2025
Baxter International USD 2.84B 30M Sep/2025
Becton, Dickinson and Co. USD 5.9B 400M Sep/2025
Boston Scientific USD 5.29B 220M Dec/2025
Cardinal Health USD 65.63B 1.63B Dec/2025
Cooper Companies USD 1.07B 4.9M Sep/2025
Dexcom USD 1.21B 50M Sep/2025
Edwards Lifesciences USD 1.55B 20M Sep/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Globus Medical USD 769M 23.7M Sep/2025
ICU Medical USD 537M 11.9M Sep/2025
Insulet USD 706.3M 57.2M Sep/2025
Integra LifeSciences USD 402.06M 13.54M Sep/2025
J&J USD 24.6B 610M Dec/2025
Masimo USD 371.5M 600K Sep/2025
Medtronic USD 8.96B 383M Sep/2025
Merit Medical Systems USD 384.2M 1.7M Sep/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Solventum Corp USD 2.1B 60M Sep/2025
Stryker USD 7.2B 1.14B Dec/2025
Tandem Diabetes Care USD 249.25M 8.57M Sep/2025
Teleflex USD 913M 132.11M Sep/2025
West Pharmaceutical Services USD 804.6M 38.1M Sep/2025
Zimmer Biomet Holdings USD 2B 80M Sep/2025